Abstract PO-129: Using the castration resistant prostate cancer patient-derived xenograft (PDX) tumor model to identify mRNA/miRNA biomarkers which distinguish abiraterone treatment responders and non-responders
2018 ◽
Vol 27
(Sup4b)
◽
pp. S1-S8
◽
2016 ◽
Vol 23
(9)
◽
pp. 2301-2312
◽
2014 ◽
2013 ◽
Vol 14
(12)
◽
pp. 1193-1199
◽